Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys

Exp Clin Psychopharmacol. 2003 Nov;11(4):286-93. doi: 10.1037/1064-1297.11.4.286.

Abstract

This study examined whether the cannabinoid antagonist, SR 141716A, could be established as a discriminative stimulus in rhesus monkeys treated with delta -sup-9-tetrahydrocannabinol (delta -sup-9-THC). Stimulus control was established with SR 141716A (1.0 mg/kg) in 3 delta -sup-9-THC-treated monkeys (1.12 mg/kg/day) in 113-124 sessions. The SR 141716A discriminative stimulus was dose related, attenuated by an acute injection of delta -sup-9-THC, and not mimicked by cocaine or ketamine. SR 141716A-appropriate responding occasioned by temporary discontinuation of delta -sup-9-THC treatment was attenuated by delta -sup-9-THC and not ketamine. The SR 141716A discriminative stimulus in delta -sup-9-THC-treated monkeys appears to be mediated by cannabinoid receptors and could be related to delta -sup-9-THC withdrawal.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anesthetics / pharmacology
  • Animals
  • Behavior, Animal
  • Cannabinoids / antagonists & inhibitors*
  • Cocaine / pharmacology
  • Discrimination Learning / drug effects*
  • Dose-Response Relationship, Drug
  • Dronabinol / pharmacology*
  • Drug Interactions
  • Female
  • Ketamine / pharmacology
  • Macaca mulatta
  • Male
  • Photic Stimulation
  • Piperidines / pharmacology*
  • Psychotropic Drugs / pharmacology*
  • Pyrazoles / pharmacology*
  • Rimonabant
  • Substance Withdrawal Syndrome / drug therapy
  • Substance Withdrawal Syndrome / physiopathology

Substances

  • Anesthetics
  • Cannabinoids
  • Piperidines
  • Psychotropic Drugs
  • Pyrazoles
  • Ketamine
  • Dronabinol
  • Cocaine
  • Rimonabant